Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

New England Journal of Medicine

Volumn 338, Issue 8, 1998, Pages 499-505

  Evans, William E ^a,b,c   Relling, Mary V ^a,b   Rodman, John H ^a,b   Crom, William R ^a,b   Boyett, James M ^a   Pui, Ching Hon ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TENIPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER REGRESSION; CHILD; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG CLEARANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; STATISTICAL ANALYSIS; TREATMENT INDICATION; TREATMENT PLANNING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; HUMANS; INFANT; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; PATIENT CARE PLANNING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TENIPOSIDE;

EID: 0032545976     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802193380803     Document Type: Article

References (25)

1. Pui C-H. Childhood leukemias. N Engl J Med 1995;332:1618-30.
2. Simone JV. Childhood leukemia as a model for cancer research. Cancer Res 1979;39:4301-7.
3. Rodman JH, Relling MV, Stewart CF, et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993;20:18-29.
4. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect. N Engl J Med 1986; 314:471-7.
5. Rodman JH, Abromowitch M, Sinkule JA, Haves FA, Rivera GK, Evans WE. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987;5:1007-14.
6. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 1987; 47:3005-11.
7. Behm FG, Raimondi SC, Schell MJ, Look AT, Rivera GK, Pui C-H. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood 1992;79:1011-6.
8. Williams DL, Harris A, Williams KJ, Brosius MJ, Lemonds W. A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet 1984;13:239-57.
9. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337:61-6.
10. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667-72.
11. Evans WE, Rodman JH, Relling MV, et al. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. J Pharmacol Exp Ther 1992;260:71-7.
12. Sinkule JA, Evans WE. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides. J Chromatogr 1983;274:87-93.
13. Evans WE, Rodman JH, Relling MV, et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991;28:Suppl 4:15-21.
14. Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993;11:287-93.
15. Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971;27:247-56.
16. Devita VT. Dose-response is alive and well. J Clin Oncol 1986;4:1157-9.
17. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16:327-36.
18. Niemeyer CM, Gelbar RD, Tarbell NJ, et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood 1991;78:2514-9.
19. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994;94:1996-2001.
20. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
21. Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 1997;52:155-63.
22. Barredo JC, Synold TW, Laver J, et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994;84:564-9.
23. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
24. Mahoney DH Jr, Camitta BM, Leventhal BG, et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group pilot study. Cancer 1995;75:2623-31.
25. Veerman AJP, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996;14:911-8.